Akero Therapeutics Inc (AKRO)
$28.12
Performance
- $28.11$29.12$28.12
0.04%
Downside
Day's Volatility :3.47%
Upside
3.43%
- $11.25$53.77$28.12
59.99%
Downside
52 Weeks Volatility :79.08%
Upside
47.7%
Returns
| Period | Akero Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 43.47% | 6.5% | 0.0% |
6 Months | 28.03% | 7.1% | 0.0% |
1 Year | -32.09% | 9.8% | 0.0% |
3 Years | 30.09% | 14.2% | -20.2% |
Highlights
Market Capitalization | 1.9B |
Book Value | $12.24 |
Earnings Per Share (EPS) | -3.24 |
Wall Street Target Price | 45.78 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -20.23% |
Return On Equity TTM | -31.11% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -204.1M |
Diluted Eps TTM | -3.24 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.81 |
EPS Estimate Next Year | -4.19 |
EPS Estimate Current Quarter | -0.95 |
EPS Estimate Next Quarter | -0.97 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 62.8%
Technicals Summary
Sell
Neutral
Buy
Akero Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Akero Therapeutics Inc | 23.51% | 28.03% | -32.09% | 30.09% | 8.42% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Akero Therapeutics Inc | NA | NA | NA | -3.81 | -0.31 | -0.2 | NA | 12.24 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Akero Therapeutics Inc | Buy | $1.9B | 8.42% | NA | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Akero Therapeutics Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 93.7%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 156.4%
Institutional Holdings
HHG PLC
8.85%RTW INVESTMENTS, LLC
7.86%General Atlantic Llc
7.57%Wellington Management Company LLP
7.54%BlackRock Inc
7.08%T. Rowe Price Associates, Inc.
5.87%
Company Information
akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.
Organization | Akero Therapeutics Inc |
Employees | 58 |
CEO | Dr. Andrew Cheng M.D., Ph.D. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$28.12
-0.71%
Keyarch Acquisition Corp
$28.12
-0.71%
Connexa Sports Technologies Inc
$28.12
-0.71%
Us Value Etf
$28.12
-0.71%
First Wave Biopharma Inc
$28.12
-0.71%
Global X Msci Next Emerging
$28.12
-0.71%
Fat Projects Acquisition Corp
$28.12
-0.71%
Capital Link Global Fintech
$28.12
-0.71%
Applied Uv Inc
$28.12
-0.71%